CD276 and neoplasm: The abnormal expression of B7-H3 is a possible biomarker and a promising immune checkpoint target for multiple cancer immunotherapy approaches, especially its expression on cancer initiating cells (CICs), since their eradication is a requirement for an anti-tumor therapy to be effective (73).